(Q47246204)

English

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years. (English)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

4

object named as

M von Eynatten

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

author name string

B Gallwitz

1

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

J Rosenstock

2

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

A Emser

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

H-J Woerle

5

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

publication date

1 April 2013

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

International Journal of Clinical Practice

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

67

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

317-321

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

4

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

The end point is just the beginning

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Counterpoint--the end point: less is more

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Hypoglycaemia in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12101

21 January 2018

Identifiers

10.1111/IJCP.12101

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/23521323

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47246204&oldid=1518365126"